Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 47: 1660-1665, 2001;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gouin-Thibault, I.
Right arrow Articles by Schlageter, M.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gouin-Thibault, I.
Right arrow Articles by Schlageter, M.-H.
Related Collections
Right arrow Hemostasis and Thrombosis
Right arrow Hematology
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2001;47:1660-1665.)
© 2001 American Association for Clinical Chemistry, Inc.

Articles

Is the Thrombopoietin Assay Useful for Differential Diagnosis of Thrombocytopenia? Analysis of a Cohort of 160 Patients with Thrombocytopenia and Defined Platelet Life Span

Isabelle Gouin-Thibault1,2, Bruno Cassinat1, Christine Chomienne1, Jean-Didier Rain1, Yves Najean1 and Marie-Hélène Schlageter1a

1 Service de Médecine Nucléaire, Hôpital Saint-Louis, Assistance Publique, Hôpitaux de Paris, 1, Avenue Claude Vellefaux, 75475 Paris Cedex 10, France.

2 Laboratoire d’Hématologie, Groupe Hospitalier Charles Foix-Jean Rostand, Assistance Publique, Hôpitaux de Paris, 7, Avenue de la République, 94205 Ivry Sur Seine Cedex 5, France

aAuthor for correspondence. Fax 33-1-42-49-94-05; e-mail marie-helene.schlageter{at}sls.ap-hop-paris.fr.

Background: Thrombopoietin (TPO), the major hormone controlling platelet production, has been measured in thrombocytopenias with discordant results. The aim of our work was to assess the value of the TPO assay for differential diagnosis of thrombocytopenias in a large cohort of patients classified according to the results of their platelet isotopic study.

Methods: We measured TPO (R&D Systems) in serum of 160 thrombocytopenic patients referred to our department for platelet life span isotopic studies. We classified patients as follows: (a) idiopathic or autoimmune thrombocytopenia group (ITP; patients with increased platelet destruction and shortened platelet life span; n = 67); (b) pure genetic thrombocytopenia group (patients with decreased platelet production, normal platelet life span, and without bone marrow aplasia; n = 55); (c) bone marrow aplasia group (BM; patients with decreased platelet production, normal platelet life span, and bone marrow aplasia; n = 13).

Results: In patients with pure genetic thrombocytopenia, TPO (median, 55 ng/L) was not different from TPO in patients with ITP (median, 58 ng/L) or controls (n = 54; median, 51 ng/L). Only in patients with bone marrow aplasia was TPO significantly higher (median, 155 ng/L) and negatively correlated to the platelet count (r2 = 0.5014).

Conclusions: Although the median serum TPO is increased in thrombocytopenia with decreased platelet production from bone marrow aplasia, it does not differentiate patients with pure genetic thrombocytopenia from those with ITP.




The following articles in journals at HighWire Press have cited this article:


Home page
 J Intensive Care MedHome page
S. S. Salman, E. R. Fernandez Perez, J. R. Stubbs, and O. Gajic
The Practice of Platelet Transfusion in the Intensive Care Unit
J Intensive Care Med, March 1, 2007; 22(2): 105 - 110.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Association for Clinical Chemistry.